

## SAFETY DATA SHEET

**Product Name: Magnesium Sulfate Injection**

### 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

<b>Manufacturer Name And Address</b>	Hospira, Inc. 275 North Field Drive Lake Forest, Illinois 60045 USA
<b>Emergency Telephone</b>	CHEMTREC: North America: 800-424-9300; International 1-703-527-3887; Australia - 61-290372994; UK - 44-870-8200418
<b>Hospira, Inc., Non-Emergency</b>	224 212-2000
<b>Product Name</b>	Magnesium Sulfate Injection
<b>Synonyms</b>	MAGNESIUM SULFATE - magnesium sulfate injection, solution MAGNESIUM SULFATE IN DEXTROSE - magnesium sulfate injection, solution

### 2. HAZARD(S) IDENTIFICATION

<b>Emergency Overview</b>	Magnesium Sulfate Injection is a solution containing magnesium sulfate heptahydrate. Clinically, this material is indicated for intramuscular or intravenous use as an electrolyte replenisher or as an anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. In the workplace, this material should be considered potentially irritating to the eyes, respiratory tract, and gastrointestinal tract. Based on clinical use, possible target organs include the respiratory system cardiovascular system and central nervous system.
---------------------------	--

#### U.S. OSHA GHS Classification

<b>Physical Hazards</b>	<b>Hazard Class</b>	<b>Hazard Category</b>
	Not Classified	Not Classified
<b>Health Hazards</b>	<b>Hazard Class</b>	<b>Hazard Category</b>
	Eye Damage / Irritation	2A

#### Label Element(s)

**Pictogram**



**Signal Word**

Warning

**Hazard Statement(s)**

Causes serious eye irritation

**Precautionary Statement(s)  
Prevention**

Do not breathe vapor or spray  
Wash hands thoroughly after handling  
Wear eye protection/face protection.

**Response**

Get medical attention if you feel unwell.

IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

**Active Ingredient Name** Magnesium Sulfate Heptahydrate  
**Chemical Formula** MgSO<sub>4</sub> • 7H<sub>2</sub>O

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Magnesium Sulfate Heptahydrate	≤50	10034-99-8	NA

Non-hazardous ingredients include Water for Injection and may include dextrose. Hazardous ingredients present at less than 1% may include sulfuric acid and/or sodium hydroxide for pH adjustment.

### 4. FIRST AID MEASURES

**Eye Contact** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Skin Contact** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Inhalation** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Ingestion** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Magnesium intoxication is manifested by a sharp drop in blood pressure and respiratory paralysis. Disappearance of the patellar reflex is a useful clinical sign to detect the onset of magnesium intoxication. In the event of overdose artificial ventilation must be provided until a calcium salt can be injected intravenously to antagonize the effects of magnesium. In adults intravenous administration of 5 to 10 mEq of 10% calcium gluconate will usually reverse respiratory depression or heart block due to magnesium intoxication. In extreme cases, peritoneal or hemodialysis may be required.

### 5. FIRE FIGHTING MEASURES

**Flammability** None anticipated for this aqueous product.

**Fire & Explosion Hazard** None anticipated for this aqueous product.

**Extinguishing Media** As with any fire, use extinguishing media appropriate for primary cause of fire such as carbon dioxide, dry chemical extinguishing powder or foam.

**Special Fire Fighting Procedures** No special provisions required beyond normal firefighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

### 6. ACCIDENTAL RELEASE MEASURES

**Spill Cleanup and Disposal** Isolate area around spill. Put on suitable protective clothing and equipment as specified by site spill control procedures. Absorb the liquid with suitable material and clean affected area with soap and water. Dispose of spill materials according to the applicable federal, state, or local regulations.

**7. HANDLING AND STORAGE**

- Handling** No special handling required under conditions of normal product use.
- Storage** No special storage required for hazard control. For product protection, follow storage recommendations noted on the product case label, the primary container label, or the product insert.
- Special Precautions** No special precautions required for hazard control.

**8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

**Exposure Guidelines**

Component	Exposure Limits			
	OSHA-PEL	ACGIH-TLV	AIHA WEEL	Hospira EEL
Magnesium Sulfate Heptahydrate	8-hr TWA: Not Established	8-hr TWA: Not Established	8-hr TWA: Not Established	8-hr TWA: Not Established

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit  
 ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.  
 AIHA WEEL: Workplace Environmental Exposure Level  
 EEL: Employee Exposure Limit.  
 TWA: 8-hour Time Weighted Average.

- Respiratory Protection** Respiratory protection is normally not needed during intended product use. However, if the generation of aerosols is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (N95 or equivalent) is recommended under conditions where airborne aerosol concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit tested and approved for respirator use as required.
- Skin Protection** If skin contact with the product formulation is likely, the use of latex or nitrile gloves is recommended.
- Eye Protection** Eye protection is normally not required during intended product use. However, if eye contact is likely to occur, the use of chemical safety goggles (as a minimum) is recommended.
- Engineering Controls** Engineering controls are normally not needed during the normal use of this product.

## 9. PHYSICAL/CHEMICAL PROPERTIES

<b>Appearance/Physical State</b>	A sterile, nonpyrogenic solution of magnesium sulfate heptahydrate in water for injection
<b>Odor</b>	NA
<b>Odor Threshold</b>	NA
<b>pH</b>	6.0 (5.5 to 7.0) for Ansyr™ Plastic Syringe 4.5 (3.5 to 6.5) for flexible plastic containers
<b>Melting point/Freezing Point</b>	NA
<b>Initial Boiling Point/Boiling Point Range</b>	NA
<b>Flash Point</b>	NA
<b>Evaporation Rate</b>	NA
<b>Flammability (solid, gas)</b>	NA
<b>Upper/Lower Flammability or Explosive Limits</b>	NA
<b>Vapor Pressure</b>	NA
<b>Vapor Density (Air =1)</b>	NA
<b>Relative Density</b>	NA
<b>Solubility</b>	Magnesium sulfate heptahydrate is a colorless crystal or white powder freely soluble in water
<b>Partition Coefficient: n-octanol/water</b>	NA
<b>Auto-ignition Temperature</b>	NA
<b>Decomposition Temperature</b>	NA
<b>Viscosity</b>	NA

## 10. STABILITY AND REACTIVITY

<b>Reactivity</b>	Not determined.
<b>Chemical Stability</b>	Stable under standard use and storage conditions.
<b>Hazardous Reactions</b>	Not determined
<b>Conditions to Avoid</b>	Not determined
<b>Incompatibilities</b>	Not determined
<b>Hazardous Decomposition Products</b>	Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of magnesium oxides (MgOx), sulfates (SOx), and hydrogen sulfide.
<b>Hazardous Polymerization</b>	Not anticipated to occur with this product.

## 11. TOXICOLOGICAL INFORMATION

**Acute Toxicity** - Not determined for the product formulation. Information for the anhydrous magnesium sulfate is as follows:

Ingredient(s)	Percent	Test Type	Route of Administration	Value	Units	Species
Magnesium Sulfate	100	LDLo	Oral	5000 3000	mg/kg mg/kg	Mouse Rabbit
Magnesium Sulfate	100	LDLo	Intravenous	48	mg/kg	Mouse

LD 50: Dosage that produces 50% mortality.

**11. TOXICOLOGICAL INFORMATION: continued**

<b>Occupational Exposure Potential</b>	Information on the absorption of this product via inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.
<b>Signs and Symptoms</b>	None anticipated from normal handling of this product. If ingested, this material may produce gastrointestinal irritation. In clinical use, the adverse effects of parenterally administered magnesium usually are the result of magnesium intoxication. Symptoms of magnesium intoxication include flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and central nervous system depression proceeding to respiratory paralysis.
<b>Aspiration Hazard</b>	None anticipated from normal handling of this product.
<b>Dermal Irritation/ Corrosion</b>	None anticipated from normal handling of this product.
<b>Ocular Irritation/ Corrosion</b>	None anticipated from normal handling of this product. However, inadvertent contact of this product with eyes may produce irritation with redness and tearing.
<b>Dermal or Respiratory Sensitization</b>	None anticipated from normal handling of this product.
<b>Reproductive Effects</b>	None anticipated from normal handling of this product. Studies in pregnant women have not shown that magnesium sulfate injection increases the risk of fetal abnormalities if administered during all trimesters of pregnancy.
<b>Mutagenicity</b>	The mutagenic potential of this product has not been evaluated. Anhydrous magnesium sulfate was negative in the Ames test for mutagenicity.
<b>Carcinogenicity</b>	The carcinogenic potential of this product has not been evaluated.
<b>Carcinogen Lists</b>	<b>IARC:</b> Not listed <b>NTP:</b> Not listed <b>OSHA:</b> Not listed
<b>Specific Target Organ Toxicity – Single Exposure</b>	NA
<b>Specific Target Organ Toxicity – Repeat Exposure</b>	Based on clinical use, possible target organs include the respiratory system cardiovascular system and central nervous system.

**12. ECOLOGICAL INFORMATION**

<b>Aquatic Toxicity</b>	Not determined for product.
<b>Persistence/Biodegradability</b>	Not determined for product.
<b>Bioaccumulation</b>	Not determined for product.
<b>Mobility in Soil</b>	Not determined for product.

Notes:

**13. DISPOSAL CONSIDERATIONS**

<b>Waste Disposal</b>	All waste materials must be properly characterized. Further, disposal should be performed in accordance with the federal, state or local regulatory requirements.
<b>Container Handling and Disposal</b>	Dispose of container and unused contents in accordance with federal, state and local regulations.

## 14. TRANSPORTATION INFORMATION

<b>ADR/ADG/ DOT STATUS</b>	Not regulated
<b>Proper Shipping Name</b>	NA
<b>Hazard Class</b>	NA
<b>UN Number</b>	NA
<b>Packing Group</b>	NA
<b>Reportable Quantity</b>	NA
<b>ICAO/IATA STATUS</b>	Not regulated
<b>Proper Shipping Name</b>	NA
<b>Hazard Class</b>	NA
<b>UN Number</b>	NA
<b>Packing Group</b>	NA
<b>Reportable Quantity</b>	NA
<b>IMDG STATUS</b>	Not regulated
<b>Proper Shipping Name</b>	NA
<b>Hazard Class</b>	NA
<b>UN Number</b>	NA
<b>Packing Group</b>	NA
<b>Reportable Quantity</b>	NA

Notes: DOT - US Department of Transportation Regulations

## 15. REGULATORY INFORMATION

<b>US TSCA Status</b>	Exempt
<b>US CERCLA Status</b>	Not listed
<b>US SARA 302 Status</b>	Not listed
<b>US SARA 313 Status</b>	Not listed
<b>US RCRA Status</b>	Not listed
<b>US PROP 65 (Calif.)</b>	Not listed

Notes: TSCA, Toxic Substance Control Act; CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act; SARA, Superfund Amendments and Reauthorization Act; RCRA, US EPA, Resource Conservation and Recovery Act; Prop 65, California Proposition 65

**GHS/CLP Classification\***      \*In the EU, classification under GHS/CLP does not apply to certain substances and mixtures, such as medicinal products as defined in Directive 2001/83/EC, which are in the finished state, intended for the final user.

Hazard Class	Hazard Category	Pictogram	Signal Word	Hazard Statement
NA	NA	NA	NA	NA

**Prevention**  
 Do not breathe vapor or spray  
 Wear eye protection/face protection  
 Wash hands thoroughly after handling

**Response**  
 Get medical attention if you feel unwell.  
 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention.

**EU Classification\***      \*Medicinal products are exempt from the requirements of the EU Dangerous Preparations Directive.

<b>Classification(s)</b>	NA
<b>Symbol</b>	NA
<b>Indication of Danger</b>	NA
<b>Risk Phrases</b>	NA
<b>Safety Phrases</b>	S23: Do not breathe vapor/spray S24: Avoid contact with the skin S25: Avoid contact with eyes S37/39 Wear suitable gloves and eye/face protection.

**16. OTHER INFORMATION**

Notes:

ACGIH TLV	American Conference of Governmental Industrial Hygienists – Threshold Limit Value
CAS	Chemical Abstracts Service Number
CERCLA	US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
DOT	US Department of Transportation Regulations
EEL	Employee Exposure Limit
IATA	International Air Transport Association
LD <sub>50</sub>	Dosage producing 50% mortality
NA	Not applicable/Not available
NE	Not established
NIOSH	National Institute for Occupational Safety and Health
OSHA PEL	US Occupational Safety and Health Administration – Permissible Exposure Limit
Prop 65	California Proposition 65
RCRA	US EPA, Resource Conservation and Recovery Act
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
STEL	15-minute Short Term Exposure Limit
STOT - SE	Specific Target Organ Toxicity – Single Exposure
STOT - RE	Specific Target Organ Toxicity – Repeated Exposure
TSCA	Toxic Substance Control Act
TWA	8-hour Time Weighted Average

MSDS Coordinator: Hospira GEHS  
Date Prepared: October 18, 2012  
Date Revised: June 02, 2014

**Disclaimer:**

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.